| Description |
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity[1][2].
|
| Related Catalog |
|
| Target |
IC50: 6 μM (Aurora kinase B), 22.3 μM (Aurora kinase A)[1]
|
| In Vitro |
Derrone (30-60 μM, 15 days) significantly inhibits the formation and growth of MCF7 tumor spheroids, with the tumor spheroid growth inhibition (% TGI) of 17.5% and 65.4% for 30 and 60 μM Derrone, respectively[1]. Derrone shows the autophagic features, such as the conversion of LC3-I to LC3-II, the formation of autophagosome and the downregulation of SQSTM1/p62 (p62)[2]. Derrone induces autophagic cell death through intracellular ROS and sustained ERK phosphorylation in A549 cells[2].
|
| References |
[1]. Hoang NT, et al. In Vitro Characterization of Derrone as an Aurora Kinase Inhibitor. Biol Pharm Bull. 2016 Jun 1;39(6):935-45. [2]. Kang MJ, et al. Derrone induces autophagic cell death through induction of ROS and ERK in A549 cells. PLoS One. 2019 Jun 19;14(6):e0218659.
|
